Hirotsu Bio Science key facts
as of Oct 2026- Developer of a cancer detection technology designed to identify small amounts of cancerous odors in urine with high accuracy.
- Hirotsu Bio Science is valued at approximately $500.0M as of Oct 2026 (last reported valuation).
- It has raised $125.5M; the latest was Secondary Transaction - Private ($60.0M) in Feb 2026.
- Notable investors include SBI Investment, Mitsui Sumitomo Insurance Co., Shinkin Capital, Aioi Nissay Dowa Insurance, As One (Japan) — 19 tracked in total.
- Status: Privately Held (backing).
Hirotsu Bio Science's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch Hirotsu Bio Science: the Monday email on marks, rounds and moves
Hirotsu Bio Science funding rounds
No funding rounds for Hirotsu Bio Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Hirotsu Bio Science
19+Hirotsu Bio Science valuation
Hirotsu Bio Science's last reported valuation was $500 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Hirotsu Bio Science investors
19 investors are on record for Hirotsu Bio Science, including SBI Investment, Mitsui Sumitomo Insurance Co., Shinkin Capital and Aioi Nissay Dowa Insurance.
About Hirotsu Bio Science
Developer of a cancer detection technology designed to identify small amounts of cancerous odors in urine with high accuracy. The company offers a revolutionary, highly accurate, and comprehensive screening test that utilizes the sense of smell of living organisms, enabling individuals worldwide to access early and reliable detection of cancer for improved health outcomes.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2016
- Employees
- 100
- Website
- hbio.jp/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.